Dr. Landovitz is chief of the Division of Infectious Diseases in the Department of Medicine at the David Geffen School of Medicine, University of California, Los Angeles. He also serves as the director of the UCLA Center for Clinical AIDS Research and Education (CARE) and the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS). As one of the protocol chairs for HPTN 077 and HPTN 083, Dr. Landovitz helped lead the NIH-funded trials that supported the 2021 FDA approval of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP).

Dr. Sybil Hosek, protocol chair for HPTN 083-01 and HPTN 084-01, is a clinical adolescent psychologist at Stroger Hospital of Cook County and an assistant professor in the Division of Infectious Disease at Rush University in Chicago. Her research interests are focused on HIV prevention among adolescents and young adults.  

Dr. Sinead Delany-Moretlwe serves as the research director at Wits RHI in Johannesburg, South Africa, and is a professor of global health and infectious diseases at the University of the Witwatersrand in Johannesburg. Her research interests span the intersections between sexual and reproductive health (SRH) and infectious diseases, particularly in adolescent girls and young women (AGYW). She served as the protocol chair of HPTN 084 and assumed the role of co-principal investigator of the HIV Prevention Trials Network (HPTN) in December 2025. 

Dr. Darrell Wheeler is president of the State University of New York at New Paltz. He currently serves on the U.S. Presidential Advisory Council on HIV/AIDS (PACHA); is a member of the SUNY Research Council; is on the HPTN Executive Management Committee; and co-chairs the HPTN Scholars Program. Wheeler earned his doctorate from the University of Pittsburgh, a master’s degree in public health, a master’s in social work from Howard University, and a bachelor’s degree in sociology from Cornell College. He served as vice chair of the U.S.

Nyaradzo Mavis Mgodi, (MBChB, MMed) is a clinical pathologist with over 10 years of experience conducting HIV clinical trials in women of reproductive age in sub-Saharan Africa, including Zimbabwe, the home of the University of Zimbabwe-Clinical Trials Research Centre, a DAIDS Clinical Trials Unit (CTU). As the lead investigator in Harare, she has overseen the implementation of several HPTN studies (HPTN 076, HPTN 082, HPTN 084) and the Microbicide Trials Network (MTN) studies assessing safety and effectiveness of oral PrEP and the dapivirine vaginal ring.